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CHAPTER 1: INTRODUCTION

Chronic Kidney Disease
Chronic kidney disease (CKD) is a long-standing, progressive (irreversible) deterioration of renal
function. It affects about 10-15% of adults in the Western world. Based on the National Kidney
Foundation of Kidney Disease, there are about 26 million individuals with CKD in the USA [1-3].
Symptoms of CKD develop slowly and include anorexia, nausea, vomiting, stomatitis,
dyspepsia, nocturia, lassitude, fatigue, pruritus, decreased mental acuity, muscle twitches and
cramps, water retention, under nutrition, gastrointestinal ulceration and bleeding, peripheral
neuropathies, and seizures. CKD should be distinguished from acute kidney failure which tends to
be most acute and reversible [4]. However, if the causes of the acute failure persist or if it is
repeated, the kidneys will deteriorate. Repeated acute kidney failure may lead to CKD.

Diagnostic Criteria of CKD
The diagnosis criteria were established by Kidney Disease Outcome Quality Initiative K/DQQI in
2002 and The National Institute of Diabetes and Digestive and Kidney Diseases. Criteria of CKD
include either evidence of progressive kidney damage or an irreversible pathologic abnormality
that persists for at least 3 months, with or without reduction in glomerular filtration rate (GFR),
and proved pathologically or clinically; or persistent reduction for three months in GFR to < 60
mL/min/1.73 m.2 Normal GFR ranges from 90 - 120 ml/min/1.73 m2
The diagnosis is made by laboratory and/or by confirming anatomical and histological
damages. The reduction of GFR of 60 to 89, 30 to 59, and 15 to 29 ml/min/1.73 m 2 defines stages
2,3, and 4 of CKD; respectively [3, 5]. A less than 15 mL/min/1.73 m2 defines end stage renal
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disease or ESRD and is an indication for dialysis. Once the GFR of an individual reaches that of
ESRD, the treatment will include a form of dialysis or kidney transplant [3, 4].

Causes of CKD
The two most common causes of CKD in the Unites States are poorly treated chronic diabetes
mellitus and poorly regulated chronic hypertension [1, 3-5]. Age remains an independent risk
factor for CKD and CKD is more prevalent among African Americans and Native Americans
because of diabetes and metabolic syndrome [2, 3].
Clinical textbooks and literatures list other causes of CKD [3, 4, 6].

Autoimmune

disorders such as systemic lupus erythematosus are major causes because the kidneys are highly
sensitive to immune reaction and antibodies [2, 7]. Glomerulonephritis is an auto immune disease
and often associated with proteinuria and/or hematuria that may be linked to autoimmunity or
microbial infection. Chronic nephrotic syndrome is associated with albuminuria [7].
Cardiovascular diseases (CVD) may be caused by reduction of blood supply (ischemia) or
to thrombo-embolic effect can lead to CKD. CVD includes hypertension, infarction,
cardiovascular failure, chronic congestive heart failure (CHF), viral and bacterial endocarditic
(often associated with auto-antibody to the kidneys and bad oral hygiene), and rarely aneurysm in
the renal arteries.
Metabolic diseases includes endocrinopathies such as hyperparathyroidism (may be a
cause or a consequence of CKD), hyper-aldosteronism (which leads to hypertension), diabetes
mellitus and metabolic acidosis. Injury or trauma that has not been properly treated could lead to
permanent damage to both kidneys [4].
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Kidney stones, when poorly treated, may lead to structural damages. Kidney stones may
or may not be calcified (Non-calcified stones may be missed by regular X-rays). Gout (uric acid),
oxalates, and other compounds may cause kidney stones and kidney damages. Repeated renal
infections or reflex infection (backward from the bladder, when associated with ascending urinary
retention that has not been treated) are common causes of CKD, notably in economically
disadvantaged communities. Rarely, parasites may damage the kidneys (immune mediated,
recurrence of hemolytic or bleeding, or direct invasion); these parasites include malaria and
Schistozomiasis [4].
Chronic obstructive uropathy may be caused by non-infectious factors. It damages the
kidneys by reflex or backward flow of urine that may be caused by an untreated and undetected
tumor (the tumor may be benign otherwise, undetected stones or other obstructive causes). This
formerly fell into post-renal conditions that cause chronic accumulation/retention of urine in the
kidneys and damage the kidneys. Obstruction may cause damage to one kidney or both kidneys. If
one kidney is damaged, chronic alteration of blood pressure and blood homeostasis may affect the
other one [2-4].
Medications, including certain anti-inflammatory and pain medications, and antibiotics,
notably aminoglycozides that are important antibiotics used intravenously to treat gram negative
bacteria, diuretics, and several cancer drugs may lead to CKD [4].
Birth defects and anomalies of the kidneys such as polycystic kidney disease or
deformation of the kidneys are rare causes of CKD. Hereditary renal and metabolic conditions
and family history of chronic kidney disease are also risk factors. Smoking is regarded as an
independent risk factor of CKD [2, 4].
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Certain toxic chemicals (other than prescribed drugs) include heavy metals such as
cadmium, mercury and platinum may lead to CKD [8]. Other chemicals include illicit drugs, toxic
herbs, polluted water and food additives. Diseases or damages to renal veins or arteries include
rare thrombo-embolic diseases with or without infarction and bleeding are rare but important
causes of kidneys damages [4, 8]. .
Malignancies may cause kidney damages either directly by dissemination and metastasis
or directly by pressure, infection (weakening of the immune system), blood flow disturbance (the
tumor may invade the renal arteries or the renal veins), bleeding, cellular lysis, hematological
manifestation, the production of immune globulins and amyloidosis. Multiple myeloma is among
the most common cancer-related causes of renal disease (both acute and chronic) by several
mechanisms including cell lysis, drug toxicity, auto-antibodies and amyloidosis. Amyloidosis
may be the cause of the death of the person. Systematic amyloidosis and para-proteinuria are
associated with chronic inflammation with or without malignancies and can cause either acute or
CKD [2, 4].
Trace mineral accumulations (notably copper) in the kidneys are possible (Wilson’s
disease). The patient will also suffer from liver and cardiac failures, which complicate CKD [8].
Other causes are often manifested with acute renal failure, but may progress into CKD if
repeated or caused irreversible renal damages. These causes include multisystem organ failure
after shock including burns, septic shock and sepsis and other causes such as severe bleeding
(repeated, if the person survives), acute pancreatitis, repeated cell lysis and uncontrolled gout,
hemolysis and rhabdomyolysis (muscle lyses), snake poisoning and any poison that lead to
disseminated intravascular coagulation and eclampsia (associated with pregnancy) [2, 4].
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Pathophysiology of CKD
The healthy rate of renal blood flow is about 400 ml/100g of tissue per minute and is greater than
other well-supplied organs such as the liver, the heart, the lungs and the brain [1]. This explains
why the kidneys are very vulnerable to harmful substances or antibodies.
Auto immune diseases are often manifested in the kidneys because of their vulnerability to
antibodies [1, 7]. An auto immune disease or a para-neoplastic syndrome (caused by abnormal
antibodies made by cancer cells as in the case of blood cancers and myeloma) may affect the
kidneys much faster, or may manifest solely in CKD, because the sensitivities of auto antibodies
and their damaging effects are higher than those of glycation [9]. An immunological reaction with
or without complex antibodies is the most potent cause of kidney damage [10], followed by tissue
hypoxia and ischemia, exogenic agents (drugs), glycation (poorly controlled diabetes mellitus),
paraproteins (abnormal proteins and immunoglobulins as in case blood cancers like multiple
myeloma), and finally genetic defects.
Based on statistical data, diabetes and hypertension are the two most common causes of
CKD in the USA [6, 11] and diabetes mellitus remains the number one worldwide [9].
Uncontrolled Diabetics is likely to cause CKD by a combination of mechanisms. Factors that
increase the risk of CKD in diabetics include glycation which directly affect the kidneys. Other
co-morbidities include increased risk of cardiovascular disease such as hypertension, recurrent
infections, poor nutrition, and other metabolic abnormalities including gout and acid-base
imbalances [3-5, 9].
Glomerular filtration requires a high pressure of blood flow at normal conditions which
makes the nephrons very sensitive to hemodynamic injuries. This would explain the damages
caused by chronic hypertension or chronic plasma overload to the kidneys.
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The descending passage of glomerular filtration and the pressure required makes the
tissues very vulnerable to extreme blood flows and volumes. If the blood flow is in excess or if
the arterioles are dilates, this can damage the nephron directly or via rupture and bleedings. If the
blood flow is reduced, this can damage the nephrons by causing ischemic disease and infarction.
This mechanism is also seen in patients with cardiovascular diseases, chronic hypertension and
other lesions of the renal blood flow. Glomerular filtration membranes have negatively charged
molecules. This acts as an electrostatic barrier and regulator to major plasma electrolytes. A
disruption in plasma electrolytes may also damage such a barrier [1, 10].
Glomerular sclerosis and fibrosis of the tubules are seen in most cases of advanced CKD.
Activation of inflammatory cells and involvement of cytokines lead to fibrosis and damage to the
renal tissue and the kidneys become unable to eliminate waste properly [10]. Wastes are toxic
(including nitrogen waste and many drugs). The retention of nitrogen waste leads to uremia.
Uremia and dialysis-induced overload of chemicals lead to an increase in oxidative stress
and inflammation via the retention of inflammatory cytokines in the plasma. Local inflammation
and cellular infiltration are associated with and complicated by systematic inflammation and
oxidation which complicates CKD [12- 14]
Based on the physiology of the kidneys, CKD also leads to disruption in water, sodium
and potassium homeostasis. CKD also leads to disruption of the renin-angiotensin-aldosterone
(RAA) and the vasopressin or anti diuretic hormone (ADH) systems. This worsens sodium,
potassium and blood pressure disturbance. CKD is also associated with calcium and phosphorus
imbalance (vitamin D is activated in the kidneys), hyperparathyroidism and bone dystrophy which
further complicate kidney failure; acid-base balance disturbance (mild acidosis). Microcytic
anemia with low hemoglobin and hematocrit is caused by the loss of erythropoietin production is

7

seen in CKD. CVD either as causes or consequences of CKD (such as hypertension) are
exacerbated. Malnutrition (which partially explains why individuals with low BMI and low
albumin and LDL have higher risk) and systematic abnormalities (neuropathies, gastrointestinal
disorders, CVD, skin and other generalized and metabolic abnormalities) are often seen in CKD
[2, 4, 15].
Effects of CKD on lipid and glucose metabolism due to oxidative stress and inflammation
are common. Insulin resistance (IR) is also found among non-diabetics with CKD and ESRD. The
toxic uremic state and the co-existing anomalies including obesity, dyslipidemia, metabolic
acidosis and vitamin D deficiency contributes to insulin resistance and complicates the treatment
of end stage renal disease [16].

Inflammation, Oxidative Stress and CKD
It is established that inflammation and oxidative stress are pathologies among all causes of CKD
[13]. They are also linked to IR and dyslipidemia [13, 14].
An old hypothesis flourished in the 1980s and proposed that ESRD causes an increase in immune
cytokine interleukin-1 (Il-1) production as a result of exposure to celluloic membranes and that
leads to hypotension in patients with hemodialysis, an increased risk of cardiovascular disease,
and protein-energy wasting [14]. Correro and Stenvinkel stated several mechanisms are involved
in inflammation among patients with ESRD. Such mechanisms include elevated C-reactive
protein production (CRP) in uremic patients, infectious agents, periodontal inflammation, and
retention of inflammatory cytokines, advanced glycation (notably in diabetics) and oxidative
stress (pro-oxidants) [14].
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The inflammation-weight loss- hypotension may also explain a paradox that ESRD
patients with higher BMI or higher blood pressure have better prognosis. Weight and blood
pressure may reflect nutritional and cardiovascular status because weight loss and low blood
pressure indicate poorer prognosis among patients with ESRD [17, 18]. Inflammation also leads
to destruction of vascular walls, increase in coagulability and abnormal plasma lipid homeostasis
[10, 19, 20].
IR adds as a novel risk factor for inflammation as stated [16] and is modulated by
overproduction of inflammatory cytokines [21]. IR is seen among obese with metabolic
syndrome, but is also associated with wasting, weight loss and dyslipidemia among patients with
ESRD [21]. A cohort study by H.-T. Kang et al. in 2010 covered 8411 participants from rural
Korean background found that IR was associated with higher TG /HDL ratio among both genders
independently of waist circumference [22].
Oxidative stress is strongly linked to inflammation, abnormal lipid profile, atherosclerosis,
adiposity and hypertension in patients on hemodialysis [13, 23]. The toxic uremic state, the
chemicals in dialytes and the lacking of antioxidant consumption such as vitamin E may worsen
oxidative stress in uremic patients [13]. Lipoperoxidation and inflammation may also be
associated with adiposity in severe CKD [23].
The nutritional status of patients with CKD and ESRD may be inversely related to the risk
of oxidative stress and should be accounted for. Some overweight patients expressed a better
survival rate which was suggested as a result of adequate calories and nutritional intake that
would include anti-oxidants [16, 17].
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Effect of CKD and ESRD on Lipid Profile
Dyslipoproteinemia and oxidation contribute to modification of LDL to oxLDL. Increased LDL
and triglyceride-rich lipoproteins are atherogenic. The accumulations of LDLs and their entry
inside the arterial wall leads to further modification such oxidation or aggregation.

LDL

oxidation and aggregation play a pivotal role in atherosclerosis [19, 24]. Modified LDLs trigger
inflammation via stimulation of immune cells and activating adhesion molecule expression of
monocyte chemotactic protein -1 (MCP-1). MCP-1 triggers the transformation of monocytes into
macrophages. Macrophages act as scavenger cells engulfing oxidized LDL, and are converted into
foam cells [25]. Foam cells and macrophages produce growth factors and cytokines including
interleukin -6 (IL-6), tumor necrosis factor (TNF), and several adhesion molecules [26]. The
adhesion molecules bind to monocytes and recruit new cells creating a vicious cycle of
inflammatory process [26]. This leads to narrowing of the arteries and increases the risk of their
rupture, dissection or occlusion.
This cycle may be countered with an adequate level of HDL notably HDL3-C [12]. HDL
is recognized as an antioxidant and anti-thrombotic that inhibits LDL-oxidation and monocyte
chemotactic protein -1 or MCP-1 production. A functional HDL may reverse the process of
atherosclerosis because HDL removes cholesterol from cells of arterial walls [27, 28] (Figure 1.1)
Patients with ESRD are at higher risk of atherosclerosis than the normal population. CVD
exists as co-morbidity, either as a cause (such as hypertension and metabolic syndrome) or as a
result of the conditions of patients of CKD. A cardiorenal syndrome has been well-described by
the American Heart Association [29]. Progressive increase in inflammatory markers and
inflammation also leads to destruction of vascular walls, as well as an increase in coagulability,
chemotaxis and abnormal plasma lipid homeostasis, which creates a vicious cycle [19, 20].
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A study was conducted comparing 55 patients in stage 5 CKD. Thirty one patients were
on hemodialysis (HD) and 24 patients were on peritoneal dialysis (PD). The study found that
patients with ESRD tend to have low HDL –cholesterol and elevated levels of VLDL and IDL
which cause an increase in triglyceride levels. The study also revealed that hemodialysis (HD)
patients tend to have less elevation of cholesterol and apo-protein B than PD patients, but the
cardiovascular outcome was similar in both groups. Patients with CKD also tend have 10-fold
elevation of oxidized LDL (oxLDL) [12].
A proposed mechanism for such abnormalities was the activation of free fatty acids
(FFAs) delivery to the hepatocyte as well as their oxidation and esterification to cytosolic
triglycerides or VLDL. This leads to an increase in apo-B production. The increase of apo-B
production leads to an increase in atherogenic VLDL and IDL. This increase in free delivery and
activation of FFAs is attributed to exposure to dialysate, IR, and/or increase in glycation
(exposure to glucose) [30] as well as generalized oxidative stress and inflammation [12]. Several
studies cited the importance of IR in pathology of CKD and dyslipidemia even in non-obese and
non-diabetic patients [12, 16, 22, 30]. Studies also found an association between a higher level of
oxLDL and a decrease in the activities of the enzymes with HDL-related antioxidant effects.
There was a decrease in HDL3-C/HDL2-C ratio in both HD and PD. The effects of these
abnormalities in lipid profile, and increase in apo-B lipoprotein and oxLDL lead to an increase in
oxidative stress and atherogenesis.
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Alteration of Major Lipoproteins in Patients with CKD and ESRD
CKD and ESRD affect individual lipoproteins and their metabolism. I list some of them and shall
discuss pertinent lipid metabolism in greater detail in the discussion section.
Alterations in metabolism of triglyceride-rich lipoprotein in predialysis and dialysis
patients are common. VLDL, chylomicrones and their remnants increase beginning in early stage
CRD. Serum triglycerides tend to be higher after meals among patients with CKD than those who
are healthy. This is often attributed to IR of patients with CKD [31]. Reduction of catabolic rate
of VLDL is also associated with low lipoprotein lipase activity and down regulation of the
enzyme gene [32, 33]. A decrease of apoprotein C-II/C-III leads to more inhibition of lipoprotein
lipase LPL (Apo C-III inhibits LL while Apo C-II activates it) [33]. Secondary
hyperparathyroidism and increased liver production of TG may also be involved [34]. The use of
low molecular heparins in HD patients contributes to abnormal catabolism of triglyceride-rich
proteins, while the use of high flux polysulfone or cellulose triacetate reduces triglycerides in HD
patients [35].
Alterations in LDL metabolism in predialysis and dialysis patients are common. They are
influenced by heavy proteinuria. The loss of albumin affects the gene expression of 3-hydroxy-3methyl-glutaryl-CoA reductase (HMG-CoA reductase), cholesterol 7 alpha hydroxylase, and
cholesterol receptors in the liver [36]. Acquired LDL receptors deficiency may also be a factor in
nephritic proteinuria [36]. Acquired CKD (in absence of proteinuria and glomerulostenosis) does
not alter hepatic LDL receptor gene expression, but may alter LDL metabolism [32]. The loss of
albumin in the urine may also stimulate the liver to produce lipoprotein B and other LDL-related
proteins. This occurs more often in peritoneal dialysis patients. A microalbunirunia is also
associated with higher risk of CVD [32, 37]. Up regulation of Acyl-CoA cholesterol
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acyltransferase or ACAT (the enzyme that esterifies free cholesterol in hepatocytes) has also been
seen in nephrotic syndrome patients along with increase in HMG CoA reductase and down
regulation of cholesterol 7-alpha hydroxylase (the rate-limiting enzyme in bile acids synthesis)
[32, 38].
HDL is also altered in predialysis and dialysis patients [32]. HDL-C plasma level is
reduced in patients with CKD and ESRD. Mechanisms of HDL alteration involve decreased
levels of apoprotein AI and AII, reduced activity of Lecithin—cholesterol acyltransferase or
LCAT (the enzyme that esterifies of free cholesterol in HDL), and an increase in Cholesteryl ester
transfer protein (CETP) activity [32, 39]. As stated before, oxidative stress and inflammation are
often increased in patients with CKD and ESRD and contribute to dyslipidemia which further
affects HDL antioxidation activity [20, 21, 23].

Treatment Options of ESRD
Treatment of CKD includes treating the individual abnormalities, symptoms and co-morbidities
that caused CKD and/or are associated with and caused directly by CKD. The treatment provides
a reliable method to remove excess wastes, subside for the roles of the kidneys by dialysis or
kidney transplant. It also involves treating co-morbidities that caused inflammation, contributed to
CKD or worsened the complications of CKD such as diabetes, hypertension, malnutrition,
infections, and other chronic diseases. Educating patients and providing them with support and
care are of importance because the disease is chronic and may have severe psychological and
social consequences. PD and HD should be assessed for safety and sterility of chemicals, lines
and dialysate (risk of infection), volume of dialysis and dialysate and for thrombo-embolic
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complication of the graft or the venous fistula. [40]. The use of medicinal and nutraceutical agents
in CKD may also be warranted.
Medical options may vary and include the use of lipid-lowering drugs to treat
hypercholesterolemia patients and improve overall cardiac mortality rate among this group of
patients [40, 41]. It also involves the use of anti-hypertensive medications such as ACE inhibitors;
the use of vitamin D to replace inadequate activation of vitamin D; the use of erythropoietin
injection to treat anemia; to eliminate and treat other causes of anemia which may implicate the
cardiovascular system and the renal system; the use of anticoagulation (baby aspirin); to monitor
the coagulability status of patients; and to use selective anti-inflammatory medications that act on
some interleukins and TNF [40].
Nutritional options are also considered. Vitamin D (stated before) is used. The use of
omega 3 fatty acids that are derived from fish oil (EPA and DHA) may be warranted because of
their anti-inflammatory status. Two studies [42, 43] found improvement in TG level and lipid
profile when using omega-3 fatty acids. Omega-3 fatty acids also improved C-reactive protein
level [42].
The effects of vitamin E supplements in CKD and ESRD were not consistent. An animal
study found an attenuation of diabetic nephropathies by tocotrienol isomers in diabetes-induced
rats [44]. An Italian clinical study found a decrease in LDL oxidation in patients undergoing HD.
Vitamin E (tocopherol) supplementation improved LDL resistance to oxidation but it did not
modify lipid profile [45]. Another human study involving vitamin E (tocopherol) supplements did
not show an improvement in C-reactive protein and pregnancy-associated plasma protein –A
(PAPP-A) markers [46]. A study using tocotrienol rich fraction (TRF) supplementation showed
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that TRF increased expression of apo A1 and reduced expression of inflammatory marker Creactive protein [47].
The use of soy supplements such as isoflavone, vitamin C, α-tocopherol, selenium, αlipoic acid, coenzyme Q 10, red grape juice, genistine and other anti oxidants and phyochemicals
have been tried [48]. Lists of antioxidants and validations of such studies may be found in the
Cochrane collaboration review [49].
The use of HD, PD or kidney transplant are the lasting choices to treat ESRD (HD is a lot
more prevalent than PD in the West). Kidney transplant remains an option considering the
patients co-morbidities, immune status, and age.

Vitamin E
Vitamin E isomers are fat-soluble compounds that can be stored. They are classified as vitamins
because humans cannot synthesize them and because they are essential [50]. The first form of
vitamin E was first isolated by Herbert Evans and Katherine Bishop at the University of
California from dark leafy vegetables and the vitamin was known to support fertility. The name
tocopherol was derived from the Greek tokos (“childbirth”) and phero (“to give forth”) and ol for
its alcohol properties [51].
Vitamin E was found to exist in many isomers. Tocotrienol isomers (T3) were found in
seed endoplasm of monocots such as wheat, rice and barley. Unlike tocopherol isomers which are
found in many plants, tree nuts and dark greens, T3 are almost exclusively found in seed
endoplasm. Palm oil and annatto contain substantial amounts of T3 [52].
The trienol or trienes relates the three unsaturated double bonds and the side chains that differ T3
from tocopherol isomers. There exist a total of four tocopherol isomers and four tocotrienol
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isomers and are known collectively as tocochromanols that are regarded among the most effective
of lipophilic phenolic antioxidants [50, 53].
All eight vitamin E isomers contain a chromanol ring. Its hydroxyl ring is responsible for
donating hydrogen that reduces free radicals. The hydrophobic side chain allows their entry into
cell membranes. Tocochromanols occurs in alpha, beta, gamma and delta forms or α, β, γ and δ.
We have α, β, γ and δ tocopherols and α, β, γ and δ tocotrienols [53] (Figure 1.2).
The biosynthesis of vitamin E occurs mainly but not exclusively in photosynthetic
organisms because certain bacteria such as Escherichia coli are capable of synthesis of
tocochromanols. Vitamin E was classified as an antioxidant and was labeled “factor 2” by
Schwarz in 1965 [54].
The abundance of α tocopherol and its anti-oxidant property led scientists to ignore nontocopherol forms of vitamin E. T3 have been poorly studied and vitamin E has been incorrectly
associated with tocopherol [51, 55].

Mechanism of Action of Vitamin E Isomers
The major anti-oxidant function of vitamin E is scavenging lipid peroxide radicals and protecting
fatty acids in cell membranes from peroxidation including light-induced lipid peroxidation during
germination and photosynthesis [56]. The Chromanol ring is a hydroxylated aromatic ring with 15
carbon-tails which characterizes this group of vitamins. It is the active radical quenching part
[57].
Vitamin E isomers are potent antioxidants. Polyunsaturated fatty acids (PUFAs) in cell
membranes are more prone to light oxidation or chemical oxidation. Lipid peroxyl radicals react
with lipids to produce hydro peroxides and oxylipins which may alter gene expression. The steps
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of this reaction are prevented by vitamin E and carotinoids. The fact that vitamin E is
hydrophobic permits it to act on lipids in cell membranes and that leads to a better cellular
stability, and membrane stability is recognized as a function of vitamin E [56, 58].
Free radicals that are generated by one-electron transfer processes may also be produced
by drugs, toxic chemicals, heavy metals, and ionizing radiation [58]. Their production may
damage lipids in cell membranes and other particles, cellular proteins, carbohydrates and DNA.
There is a relation between those chemical reactions because oxidized lipids would alter gene
expression and thus protein synthesis. Oxidized vitamin E that picks up the free radicals is
reduced back to its original form with the presence of ascorbic acid (vitamin C) and glutathione
[56]. This is another important point to conclude that vitamin E acts in concert and harmony with
fat-soluble vitamin A and other carotinoids and does require, in return, water soluble antioxidant
vitamin C. A nutritionally-sound diet should include a harmony of the three anti-oxidant vitamins
(Figure 1.3).
Vitamin E isomers in animal cells exert similar anti-oxidative cycles as observed in plants.
They also aid in stabilizing animal cell membranes. The redox cycle involves other compounds
notably coenzyme Q 10 because there is a direct anti oxidative effect of vitamin E in
mitochondria as well. It has been shown that coenzyme Q 10 acts as peroxyl scavenger that is
formatted by superoxide-driven reaction. This prevents the reaction of pro-oxidant of phenoxyl
radicals of vitamin E in LDL [59]. Actions of T3 have also been attributed to their unsaturated
isoprenoid tails that lead to a better uniformity of the distribution in membrane layers, stronger
effectiveness on their lipids, effectiveness on radicals and better recycling activity and inhibition
of lipid oxidation [60].
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T3 penetrate cell membranes more efficiently than tocopherol isomers and their
unsaturated chains make them more accessible to tissues that are rich in saturated fatty layers
including the brain and the heart [61]. It was found that T3 in particular have significant reduction
of thiobarbituric-acid-reactive substances (a product of oxidized PUFA) in the serum of patients
with carotid stenosis [62].

Absorbance and Availability of Tocopherols and T3:
When vitamin E is obtained from food, it will be transported to the liver to be sorted out to its
isomers [58]. The endogenous lipoprotein that carries most of vitamin E inside the body is LDL
and triglyceride-rich fractions (TGRF) [63, 64].
After normocholesterolemic women received an oral vitamin E capsule (containing 77 mg
α-tocotrienol, 96 mg δ-tocotrienol, 3 mg γ-tocotrienol, 62 mg α-tocopherol and 96 mg γtocopherol), the isomers level peaked four hours after. It was found that α-tocopherol had the
largest concentration among all six isomer, α-tocotrienol had the largest concentration among T3
and that T3 were found in all lipoprotein notably in LDL [14]. It was concluded that α-tocotrienol
is the most available tocotrienol isomer in healthy human plasma lipoproteins while α-tocopherol
was the most abundant of all [63, 65].
Once released from lipoproteins to target cells, they will bind proteins that aid in
transporting vitamin E isomers inside the cytosol. When inside the cell, vitamin E is also placed
in the hydrophobic site of cell membranes.
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The multifaceted roles of T3
Current studies reveal that the vitamin E family isomers have many functions in addition to their
anti-oxidative functions, such as an effect on platelet adhesion and kinase enzymes [51].
T3 have structural activities unseen in those of tocopherols. The double-bond carbons at 3, 7, and
11 that are found in T3 allow them to have better and wider activities than tocopherol isomers
because they can better penetrate the cell membranes. The three double-bonds and unsaturated
side chains allow them easy access and movement to cell membranes [60, 65]. These
characteristics are related not only to the saturation of the chain, but also to the methylation of the
ring [65]. It was found that δ-tocotrienol has a higher or equal biological action to those of γtocotrienol; which in return are more biologically active in descending order than those of αtocotrienol, δ-tocopherol, and α-tocopherol [66].
Molecular targets of T3 are either modified by direct binding, by modulation or by indirect
modulation [53, 67]. Modulation includes transcriptional, translational, post-translational level or
may occur via direct interactions with various cellular targets. Examples of direct binding include
the effect on HMG-CoA reductase.
Inflammatory transcription factors and their genes are modulated indirectly. Studies
demonstrated that T3 possess anti-oxidant, anti-inflammatory, antiproliferative, antisurvival,
antiangiogenic, and pro-apoptotic activities [51, 53, 67]. This makes T3 more pleiotropic (having
many multifaceted physiological effects) nutrients than tocopherol isomers.
The antioxidant activity of T3 includes the induction of various enzymes such as
superoxide dismutase and glutathione peroxidase. Animal studies found that T3 notably γtocotrienol expressed antioxidant activities as well as antihypertensive activities [53, 68].
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Animal studies also demonstrated that T3, notably γ and δ, carried more wide antiproliferative and anti-cancer activities on breast cancer cell lines than α-tocopherol [69]. Studies
also found that T3 carry anti inflammatory activities including that of the effect on activation and
transcription factor NF-κB, the suppression of the expression of TNF, interleukins 1, 6 and 8,
induction of nitric oxide synthase and cyclo oxygenase 2 (COX 2). The effect of gammatocotrienol on NF-κB that transcribes for many inflammatory markers is also cross-linked to its
anti-cancer anti-apoptotic effect [70].
There is a significant importance of the anti-oxidative and the anti-inflammatory
properties of T3. Patients with CKD and ESRD have increased inflammation and oxidative stress.
These changes are fundamental parts of the pathology and pathophysiology of an abnormal lipid
metabolism in these patients [71].
This section will review findings in literatures that are pertinent to the effect of T3 and
lipid metabolism and lipoproteins. As noted earlier, T3 suppress HMG-Coenzyme-A reductase,
the rate limiting enzyme in cholesterol synthesis. The hypocholesteromic effects of T3 were
attributed to the post-transcriptional modification of the rate limiting enzyme HMG Coenzyme A
reductase. Mechanisms involve enhancing the degradation of the enzyme and reducing the
translation of its mRNA. There have also been links between anti-tumor property and HMG-CoA
reductase inhibition of tocotrienol [53].
Lipid lowering effects of T3 were first studied on animals and cell lines. Two studies by
Qureshi (1991, 2001) [72, 73] demonstrated that T3 in rice bran and tocotrienol-rich-fraction
(TRF) of palm oil may lower plasma cholesterol in pigs with hypercholesterolemia. The pigs were
fed a standard diet with 50 micrograms/g TRF obtained from palm oil. There was a 60%
reduction in LDL-cholesterol, 44% reduction in total cholesterol with 26% reduction in
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apoprotein B. This effect lasted in hypercholesterolemic pigs after 8-week consumption of the
control diet. Animal studies also demonstrated that T3 suppress HMG-CoA reductase with better
protective effect of gamma and delta tocotrienols than alpha and beta isomers. Qureschi also
demonstrated that T3 inhibits lipopolysaccharide-induced cytokines in macrophages in female
mice and that T3 were superior in their enzymatic activity than that of α-tocopherol in female
mice [74].
Another study by Khan et al on Syrian hamsters in which tocomin (mixed of 4 isomers of
T3) was administered to the animals 10 days before and 12 hours after bacterial
lipopolysaccharides or 24 hours after zymosan or turpentine to induce inflammatory reaction.
Results showed that T3 reduced plasma lipoprotein lipids, cholesterol, apoprotein B, small dense
LDL and LDL in animals who were hyperlipidemic [75]. Not all early T3 studies showed lipid
lowering effects of T3. Mensink et al conducted a double-blind placebo-controlled parallel trial on
20 men with elevated plasma cholesterol levels. The study showed that T3 had no effect on
plasma lipoprotein status [76].
T3 cell studies also demonstrated direct effects on triglyceride. Burdeos et al found that T3
attenuate triglyceride accumulation in HepG2 and rats, and that γ-tocotrienol down regulated fatty
acid synthase in Hepatoma G2 cells that received it. There was similar expression in the protein
expression of the gene that codes for that enzyme [77]. Zaiden et al showed that gamma and delta
T3 reduce hepatic triglyceride synthesis and VLDL secretions in human hepatocarcinoma cell
lines. They suggested that discrepancies between in vivo and in vitro studies may be due to the
rates of post-absorption of T3 [78].
An animal study by Kuhad et al found that T3 were more effective than α-tocopherol in
diabetic rats with nephropathy (damage in the kidneys). T3 were given at a dose of 25, 50 and 100
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mg/day to streptozotoci-given diabetes-induced rats. This prevented the progress of diabeticnephropathy in a dose-dependent fashion. Adding insulin to T3 produced better effects than
insulin alone in treating diabetes [44].
Clinical studies were thus warranted to demonstrate the effects of T3 on human lipid
profile. It has already been stated that early studies of T3 on humans were not only limited, but
also gave contradictory results [76, 79]. Qureshi conducted a double-blind crossover 8-week
human study. The subjects received either a 300 mg/corn oil or a 200 mg TRF capsule per day.
The results showed beneficial effect of TRF and a 31% reduction of plasma cholesterol was noted
in seven hypercholesterolemia subjects during the four-week of receiving the TRF
supplementation [80]. Chen and Qureshi also demonstrated that isolated T3 from rice bran had a
cholesterol-reducing effect. Such an effect also has been noted in amaranth oil. The study of
which hypercholesterolemic individuals placed on the American Heart Association step-1 diet and
also receiving statin drug lovastatin and TRF resulted in a significant improvement in lipid
parameters with an increase in HDL/LDL ratio by 46%, and without side effect of the statin. The
study showed that a dose of 100 mg/day of TRF lowered serum total cholesterol, LDLcholesterol, triglycerides and apoprotein B, suggesting the possible use of a smaller dose of TRF
plus American Heart Association step-1 (AHA step-1) diet to control risk factors of coronary
heart disease in hypercholesterolemics [81].
Unlike the success studies of Qureshi, there existed studies demonstrated that T3 did not
successfully affect cholesterol homeostasis [76, 79]. After Mensink’s study 1999, another study
by Mustad et al, (2002) demonstrated that supplementation with 3 different tocotrienol
supplements did not improve lipid levels and CVD risk factors in humans with
hypercholesterolemia [79].
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Equally interesting was a tocotrienol study on HDL-cholesterol. TRF supplementation in
healthy older adults raised plasma HDL as early as 3 months [82]. The study involved recruiting
62 subjects from two different age groups: 35-49 years and above 50 years of age. Each group
was given either TRF or a placebo at random for six months. The result showed a statistically
significant elevation in HDL-cholesterol after 6 months of TRF supplementation as compared to
the placebo among the younger group and an improvement of HDL-C to total cholesterol ratio in
both groups. It also showed reduction in oxidative stress.
Another study demonstrated that supplementation with TRF altered plasma levels of
apoprotein-A1 precursor (apo A-1 unique to HDL), apolipoprotein E precursor, and C-reactive
protein (CRP) precursors in young (32 ±2 year old) and old (52±2 year old) individuals. The
study concluded that TRF does not only alter and increase plasma levels of tocopherol and T3, but
also up-regulated apoA1 and down regulated CRP in the older individuals. Such results are
favorable for atherosclerosis prevention [47]. The kidneys are the major organs that filter apo-A1.
ApoA1 proteins are released by the action of lipase on HDL, which are enhanced by CETP and
are catabolized in the kidneys [83].

T3 and Lipoprotein Metabolism
The previous section included studies that covered cell lines, animals and some clinical studies. It
is of an importance to state major findings obtained from literatures on the effects of T3 on
lipoprotein metabolism because dyslipidemia and CVD are higher in patients with CKD and HD
[84].
Lipid lowering effects of T3 were observed in animal studies, and revealed that T3
suppress or down regulate HMG-CoA reductase, lower synthesis and increase degradation via
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post transcriptional effect [85]. Human studies demonstrated stronger effect of gamma and delta
tocotrienol. Effects of T3 on HMG-CoA reductase were contradicted by high dose of alpha
tocopherol. T3 also lowered apoprotein-B levels [84, 86]. As previously stated, data from T3
studies were not always consistent [76, 79].
The contradictory effects of T3 on plasma lipids may be attributed to the followings: 1)
Differences in absorption because absorption may increase when taken with meals. 2) Doserelated effect (in many cases. lower doses may have been required). 3) Clinical condition of the
individuals. 4) Difference of tocotrienol isomers absorption between animals and humans. 5)
Duration of the study (not long enough to produce results). 6) Metabolism of T3 and their effect
may be varied [84].
CRP, an acute phase protein and a major inflammatory marker in CVD and is implicated
in re-stenosis of coronary arteries. CRP is synthesized in the liver and regulated by tumor necrosis
factor-α TNF and IL-6 [87]. Tocotrienol isomer gamma showed 20-50 % higher potency in
reducing CRP than that of tocopherol alpha in diabetics with CVD [71, 87]. T3 also inhibited
LPS-induced secretion of TNF and IL6 in macrophage of mice and a low concentration of alpha
tocotrienol reduced IL-6 and cytokines by TRF alpha, gamma, and delta tocotrienol [74]. Palm oil
TRF also reduced the transcription of IL-4, IL-8, TNF-α and NFκB [88].
T3 alpha showed antioxidant activities such as an effect on peroxyl radical scavenging
activity being 1.5 times higher than alpha tocopherol, effect on Fe (II)-NADPH-induced lipid
peroxidantion of alpha T3 is 40 times higher than that of alpha-Tocopherol [60, 84]; and effect on
cytochrome P450 is 6.5 times higher than tocopherol [89].
T3 have antihypertensive and anti-diabetic effects in rats [53, 84]. Both diseases are major
risk factors for CVD and CKD. Glycation that is associated with poorly controlled diabetes may
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be improved or reduced by T3. Gamma and delta T3 had demonstrated a strong effect in
advanced glycosylation-end products reduction in non-diabetic rats [90]. Vitamin E (including αtocopherol) also reduces the serum level of age glycation products (AGE) in patients on HD [91].
The antihypertensive activity of T3 may be attributed to its anti-oxidant effect and its
effect on nitric oxide [68, 92]. This anti-oxidant effect plays a role in both diabetes and
hypertension. T3 have an effect on adhesion activity. Cellular adhesion is affected by oxidative
stress and is an essential part of the mechanism of atherosclerosis and CVD that shall be
discussed later. Alpha-tocotrienol is more effective than alpha-tocopherol as a result of the
suppression of selectin and vascular cell adhesion molecule that are responsible for foam cell
formations. T3 are collectively more effective than alpha-tocopherol [93].

Potential Clinical Uses of T3
Potential uses of T3 as a preventive drug have been reviewed with consideration to their structure
and their bioavailability. Literatures listed some potential cardio-protective implications of the
uses of T3 [84, 86, 94-96]. The use of T3 on atherosclerosis in patients with carotid stenosis with
palm oil revealed that 30% of patients showed regression 6% showed progression and 56%
showed no change. Direct suppression of atherosclerosis was seen in animal studies. These effects
have been attributed by various mechanisms (effect on lipids, HDL, cytokines, antioxidant, antiinflammatory, anti-chemo taxis, anti-adhesion and anti-glycosytion) [84, 86, 94, 96]. Tocopherol
in experimental animals did not regress atherosclerosis. The conversion of tocopherol to a prooxidant that may also lower vitamin C reduces the effect of glutathione peroxidase enzyme.
T3 also affect plaque stabilization, as a result of their lipid-lowering effect, antiinflammatory and anti-adhesive. Despite the limitations of human clinical studies, animal studies
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were promising. The effect on expression of MMPs and cell adhesion may be promising. There
was an ischemia-reperfusion effect because free radicals have negative effect on post-ischemic
disease. T3 might affect ischemic reperfusion due to its anti-oxidant effect. Anti-thromboembolic
effect of T3 (effect on platelet aggregation), and effect of post angioplasty and post-cardiac injury
(anti-proteasomes) were also studied [86, 94]. Not all T3 have equal effects. It was found that α
and γ T3 have better cardio protective effect than the other two isomers. The lipid modulating
effect of T3 was notably seen in the γ and δ isomers [84, 86].
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Source: Barter, 2005
Figure 1.1: HDL and atherosclerosis
Inhibition of atherosclerosis by high density lipoprotein HDL removes cholesterol from foam
cells, inhibits the oxidation of low density lipoprotein, and inhibits adhension molecule MCP-1
and monocyte chemotaxis protein.
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Source: Aggrawal et al, 2010.

Figure 1.2: Structures of tocopherol and tocotrienol isomers.
All eight vitamin E isomers contain chromanol ring. Its hydroxyl ring is responsible for donating
hydrogen that reduces free radicals. The hydrophobic side chain allows their entry into cell
membranes. Tochochromanols occurs in alpha, beta, gamma and delta forms or α, β, γ and δ. We
have α, β, γ and δ Tochopherols and α, β, γ and δ Tochotrienol isomers. The double bond carbons
at 3, 7 and 11 that are found in tocotrienol isomers allow them to have better and wider activities
because they can better penetrate the cell membranes. Actions of tocotrienol isomers (T3s) have
been suggested due to their uniformity of the distribution in membrane layers, stronger
effectiveness on their lipids, and effectiveness on radicals, better recycling activity and inhibition
of lipid oxidation.
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Source: Falk et al, 2010.

Figure 1.3: The antioxidant mechanism of vitamin E.
Vitamin E (Tocopherol) isomers regulate redox homeostasis and gene expression by modulating
the extent of lipid peroxidation in leaves. They prevent lipid peroxidation by scavenging lipid
peroxyl radicals and by reacting with other reactive oxygen species in cooperation with
carotenoids. The antioxidant activity of vitamin E is supported by the ascorbic acid–glutathione
(Asc-GSH) cycle. The cycle frees Tocopherl from the radical.
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CHAPTER 2: MATERIALS AND METHODS
Study Goal and Justification
The goal of this study was to evaluate the effect of TRF on the lipid profile in chronic kidney
patients on HD. The study justifications were based on the following:
1. Tocotrienols are known to have anti-inflammatory and anti-oxidant properties with
potential lipid-modifying effects [53, 84, 86].
2.

Most T3 studies were conducted on animals or cells. Khosla et al and Fairus et al
studied the postprandial bioavailability of T3 in human [63, 65]. Qureshi et al
found a lipid-lowering effect of T3 on humans [80, 81]. One study involved TRF
and presented evidence that T3 may benefit lipid profile and improve apoprotein
A1 expression (HDL) [94]. There are limited human studies evaluating T3 on
patients on HD [51].

3. CKD is associated with dyslipidemia, inflammation and oxidative stress [12-14, 32].
T3 have more potent antioxidant and anti-inflammatory effects than tocopherols [5153]. The current study was an attempt therefore to document the effect of TRF on
inflammatory markers, oxidative stress and lipid profile in patients with ESRD who
are under treatment by HD.

Patients
One hundred and eighteen patients were screened from the Great Lakes Dialysis Center, LLD
(Detroit, Michigan). Study criteria included age (must be an adult no less than eighteen year old),
duration of dialysis (at least three months), not living in a nursing home and receiving tube
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feeding or intradialytic parenteral nutrition and not taking dietary supplements that contain
vitamin E.

Study Design and Flow
A randomized, placebo controlled, double-blind parallel trial was conducted. The study was
approved by the Human Investigation Committees of Wayne State University and the Human
Investigation Committees of Great Lakes Dialysis, LLC. All patients signed an informed consent
before the beginning of the study (Figure 2.1). The study lasted sixteen weeks.
A total of eighty eight patients (43 males and 38 females) were eligible and met the
criteria. Patients were assigned to placebo (P) (n=40) and (TRF) (n=41). The average age of our
patients was 59±12 year old with no significant differences between the placebo and the TRF
groups. Average mass was 85±23 kg for placebo group and 90±26 kg for TRF group. There were
43 males (23 P and 20 TRF) and 38 females (17 P and 21 TRF). Eighty patients were from an
African American background, and one was Caucasian. Fifty one patients were diabetics (25 P
and 26 TRF).
Subjects were divided into TRF and placebo groups. Forty one subjects received two
capsules of 110 mg/day of TRF supplements per day. Each palm TRF soft gel contained 90 mg
tocotrienol isomers (34% α, 3% β, 50% γ and 13% δ) and 20 mg α-tocopherol. Forty subjects
received placebo capsules made from wheat germ oil providing 0.24 mg tocotrienol and 0.44 mg
tocopherol. Each subject received either 2 TRF capsules or 2 placebo capsules at the start of each
dialysis, thrice weekly. For non-dialysis days, each patient was given a pill organizer that
contained either TRF or placebo capsules. They were distributed on site at time of dialysis.
Instructions were given to take the pills during lunch and dinner (the two main meals). Patients

31

returned the pill organizer and received a new refilled one every week. The remaining (non-used)
pills were counted and tracked. Pill counting followed previously prescribed methodology [42,
97].
One patient from the placebo group suffered diarrhea during week one of the study, one
patient from the TRF group was excluded after week one because of catheter dysfunction. One
patient from the TRF group refused to continue after week four. Two patients from placebo group
passed away from cardiac arrest (week three and week twelve).
Anthropometric measures were obtained at baseline, week-8, week-12 and week-16. The
study was accompanied by 24-hour dietary recall during baseline (week zero) and week sixteen.
Dietary intake was obtained by the same registered dietitian from all subjects.

Laboratory Assessments
Blood was drawn and collected at weeks zero (baseline), eight, twelve and sixteen. Blood
collection tubes contained EDTA and lithium heparin (BD Franklin Lakes, NJ). Plasma samples
were isolated by centrifugation at 2800 rpm for 20 minutes at 4°C. Plasma was divided into
aliquots and stored at -80°C for further studies. Standard renal profiles such as serum albumin,
blood urea nitrogen, kt/v (dialysis clearance per time/volume, and creatinine), cell blood count
(CBC), hemoglobin and hematocrit were analyzed by an external laboratory (Satellite Laboratory
Services, Redwood City, CA) using standard automated techniques.
Antioxidant capacity thiobarbituric acid reactive substances (TBARS) standard kit was
used to measure malondialdehydes generated from oxidized lipids (MDA). Inflammatory markers
Interleukin-6 (Il-6), C-reactive protein (CRP), tumor necrosis factor (TNF), and nuclear factor
kappa B (NF-κB) were also measured.
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Lipid profiles including plasma triglycerides (TG), total cholesterol (TC), and high density
lipoprotein-cholesterol (HDL-C) were measured using enzymatic kits (Pointe Scientific Inc.,
Canton, MI). HDL-C was measured in the supernatant after precipitation of apoprotein-B
containing lipoproteins by dextran sulfate and magnesium ions (Pointes Scientific Inc., Canton,
MI). Plasma low density lipoprotein-cholesterol (LDL-C) was calculated using the Friedwald
equation [LDL-C= TC – (HDL-C) – (TG/5)].
Cholesteryl ester transfer protein (CETP) activity in the plasma was measured using
astandard kit as per manufacturer’s protocol (BioVision, Mountain View, CA). Briefly, plasma
samples were incubated at 37°C with a donor molecule containing a fluorescent self-quenched
neutral lipid that was transferred to an acceptor molecule in the presence of CETP which resulted
in an increase in fluorescence. Intensity of fluorescence was measured using fluorometer with
excitation set at 465 nm; and emission at 535 nm (Tecan, Switzerland). CETP activity was
quantified and expressed as picomoles per microliter of plasma per hour. Apo-protein A1 (apoA1)
was measured using a double antibody sandwich ELISA method and followed the protocol
described by the manufacturer. (Immunology Consultants Lab Inc., Portland, OR).
Microsoft office word 2007 and Microsoft Office Excel 2007 were used for data
processing and graphing. Statistical analysis was obtained using SPSS (v16; IBM, Chicago, IL).
Mean differences of the two groups were tested with independent t-test. Data were obtained using
mean±standard. Difference between two time-points such as difference between baseline and
week 12 was calculated using parallel t-test. Correlation tests were calculated using Pearson’s
correlation test. P values of < 0.05 was statistically significant.
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Screened for eligibility
(n=118)
Excluded (n=37)
•Did not met inclusion criteria (n=30)
•Declined to participate (n=7)

Randomization
(n=81)

Allocated to Placebo
(n=40)

Allocated to T3
(n=41)
Excluded (catheter dysfunction)
(n=1)

Refused to continue (n=1)
Unable to take capsule (very sick) (n=1)

Week 1

Baseline

1 pt c/o diarrhea – but willing to
continue the study
Week 3

Died (n=1) (Cardiac arrest)
Underwent transplantation (n=1)

Week 12

Died (n=1) (Cardiac arrest)

Week 4

Week 8

Week 12
Analyzed (ITT)
(including drop out)
(n=40)
Figure 2.1: Flow chart of the study.
(May Daud, 2013)

Week 16

Analyzed (ITT)
(including drop out)
(n=37)
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CHAPTER 3: RESULTS AND DISCUSSION
Lipid Analysis
Blood samples were collected from 40 P and 40 TRF on week zero (one patient was excluded
because of catheter infection), P=36, TRF= 39 on week 8, P =34, TFR= 38 on week 12 and P =29,
TFR= 38 on week 16. All lipid analyses’ quantitative results are presented in Table 3.1.
Plasma TC had a baseline average 183 mg/dl in TRF group and 179 mg/dl in P group.
Both levels were reduced during week eight and twelve. By week sixteen, TC had an average of
145 mg/dl in TRF group and 150 mg/dl in P group. The independent t-test statistical analysis of
total plasma cholesterol did not show significant difference between the two groups.
Total plasma TG was higher among the TRF group at the initial start (average 153 mg/dl
TRF vs. 110 mg/dl P). Throughout the study, TG level remained higher among the TRF group.
There was a reduction in TG to an average of 104 mg/dl TRF vs. 96 mg/dl Placebo in week
sixteen. The decline of TG level during week twelve and sixteen was more noticeable in the TRF
group because it revealed a sharper decline by about 50 mg/dl in TRF as compared to 14 mg/dl in
P from baseline. We normalized plasma TG because there was significant difference at starting
TG values between TRF and P group (Figure 3.1).
Total plasma HDL-C had a baseline average 42 mg/dl in TRF group and 44 mg/dl in P
group. There was a statistically significant increase in HDL-C during week twelve among the
TRF group (65 mg/dl) compared to 55 mg/dl in the placebo. HDL-C remained higher among the
TRF in week sixteen (Figure 3.4). We normalized HDL-C for further analysis and that revealed
an increase among TRF group at week twelve and sixteen (Figure 3.2).
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Total plasma LDL-C revealed a gradual reduction in LDL-C among both groups with
results of 75 mg/dl among P as compared to 66 mg/dl among TRF in week sixteen. Independent ttest did not show a statistical significance.
Plasma TC/HDL-C baseline ratio was higher in the TRF group than that of P group. It
declined among the TRF group during the latter two weeks (2.30 week twelve and 2.60 week
sixteen among TRF as compared to 2.80 and 2.81 among P). Normalization of TC/HDL-C ratio
showed decline of TC/HDL-C ratios in TRF group at week 12 and 16 (Figure 3.3).
Inflammatory markers were non-significant (excluding the baseline of NFκ-B with a
p=0.004). We also observed changes in oxidation in total antioxidant capacity week twelve with a
p value of 0.027. There may be several reasons that explain what we found. 1) Some patients
may have received a lower dose of T3 per weight. 2) HD and the co morbidities may modify
metabolism and duration of TRF among patients.
Newly born VLDL is released from the liver in order to transport endogenous lipids.
VLDL acquires apoprotein E (apo E) and apoprotein C (apo C) from HDL. Apo E aids in
attaching VLDL particles to the cells of the endothelium the liver. Apoprotein CII (apo CII)
activates lipoprotein lipase (LPL) while apo CI and CIII inhibits it [98]. VLDL releases TG under
the effect of LPL into the intimae of the small vessels of muscles, adipose cells and the heart. The
rest converts to intermediate-density lipoprotein (IDL) and subsequently to LDL. LDL is rich in
cholesterol and low in TG. LDL delivers cholesterol to tissues for synthesis and maintenance
[19].
Numerous studies found that ESRD and HD patients have impaired clearance of VLDL,
which leads to its accumulation and further vulnerability to oxidative stress. The impaired
clearance results in a delay in its catabolism [12, 32, 98], which is associated with dissemination
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of oxidative stress and circulating oxidized lipids [39]. A decrease of apo C-II/ apo C-III ratio also
leads to more inhibition of LPL [32]. LDL resulting from abnormal catabolism of VLDL tends to
have structural abnormalities such as the presence of small dense LDL particles [98, 99]. HD
patients have similar LDL-C level findings to those with CKD. There remains controversial
whether small LDL articles tend to be more atherogenic than those larger articles [100]. There is
decreased level of LDL receptors and expression of cholesterol clearance from the liver among
patients with ESRD [72, 104]. It is the quantitative rather than the qualitative alterations of LDL
that becomes troublesome. The same studies also found that LDL-C levels may be lower among
some HD patients, but tend to be higher in those with nephrotic syndrome [32, 98]. Our data
revealed that LDL-C levels did not express significant changes between the P and the TRF
groups.
There is a deregulation of lipoprotein receptors and their regulatory transcription factors
and enzymes (SREBP1 and 2 and HMGCR) in patients with HD and ESRD [38, 101, 102]. It
contributed to an increased level of TG among HD patients [101, 102]. The fact that TRF group
has a lower normalized TG levels would imply a potentially suppressive role of TRF on these
regulators. This potentially includes those of upstream regulators of lipid homeostasis (SREBP
1/2, HMGCR, APB100, DGAT2), which would require future studies [103]. Such abnormalities
also lead to an increase in uptake of oxidized lipids and lipoprotein into arterial and renal tissues
and is also mediated by increased levels of pro-inflammatory cytokines.
The increase of plasma HDL-C among TRF groups prompted us to analyze the function
of CETP in order to explain the activity of TG-cholesterol ester (CE) exchange between apo B
carriers (VLDL and LDL) and apo A1 carrier (HDL). Numerous studies revealed that CETP has
dual effects on lipid metabolism. It can act as pro-atherogenic because it increases CE transfer to
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apo B-containing protein, small LDL-C and modifies HDL-C. It also act as anti-atherogenic
factor because of its effect on enhancing LDL-receptors and LCAT which is an enzyme involved
in reverse cholesterol transfer (HDL formation) [104, 105].
The role of HDL is to remove excess cholesterol from extra hepatic tissues. These tissues
are unable to metabolize cholesterol [19, 106]. The major apolipoprtein in HDL is apo A1. It is
secreted from the liver to the plasma in a low-lipid form. Then, lipids are added to the inside to
produce a complete HDL molecule. The first step is to transfer phospholipids and unsterilized
cholesterol from tissues to generate the nascent HDL (discoid). This step is mediated by ATP
binding cassette transporter A-1 (ABCA 1) [19]. The discoid HDL piles up unesterified
cholesterol from other lipoproteins. Apo A-1 activates several enzymes including lecithin
cholesterol acyltransferace (LCAT) which causes the esterification of free cholesterol inside HDL
and changes HDL form to a spheroid. Spheroid HDL is rich in cholesterol esters in its center.
Apo A-1 and apo A-II (which is also synthesized in the liver) bind together and add to the
structure of the spherical apo A-1 and apo A-2 rich HDL [19, 83, 106].
The liver picks up cholesterol from HDL via scavenger receptor B1 (SR-B1) and
transform it into bile salts for excretion. The rate-limiting enzyme is a cytochrome p-450
mediated oxidation of cholesterol known as cholesterol 7 α hydroxylase. Apoprotein A1 is also
catabolized by the kidneys. Lipid-poor apo A-1 are filtered at the level of the glomerulus and then
catabolized by the proximal tubules [83]. The protein cubilin binds HDL Apo A-1 at a great
affinity, interacts with a receptor megalin (related to a low-density lipoprotein receptor families).
Cubilin is also the endocytic receptor for intrinsic factor for vitamin B12 [107]. This leads to
uptake and catabolism (degradation) of apo A1 [107]. The rate-limiting step of apo A-1 clearance
is the glomerular filtration level which explains the increase in apo A-1 and catabolic rate in
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patients with ESRD [107]. Another pathway to transfer lipids from HDL is carried out by hepatic
lipase (HL) which hydrolyzes triglycerides (TG) and phospholipids (PL) from HDL [83]. When
HDL is rich in TG, this mechanism kicks in at the hepatocytes. This process is also mediated by
an increase in CETP activity and mediation to exchange between HDL-cholesterol and TG from
apo-B rich lipoprotein. The exchange results in an increase in TG in HDL and increase in
cholesterol in apo-B containing lipoprotein which increase the risk of atherogenesis [19, 83, 106].
CETP and HL favor a small sized and less stable HDL including the generation of HDL3, β HDL
and apo A-1 [108-110]. Thus CETP does not only exchange cholesterol and triglycerides, but also
alter the size and the function of HDL and release apo A1 [111].
An increase in HDL-C among TRF group may be caused by delayed HDL catabolism or
higher cholesterol levels in HDL, which resulted from decrease or alteration in CETP activity.
Our data showed significant increase in apo A1 level among TRF group during week twelve. We
saw higher plasma apoA1 level on week twelve among the TRF group (Figure 3.4). This increase
corresponds with the increase of HDL-C in TRF group in week twelve because apo A1 is the
main apoprotein in HDL molecule [83, 108]. The increase of apo A1 among TRF group warrants
further studies because effects of T3 on apo A1 in patients with HD is not well studied. We
speculate possible effects on transcription factors such as PPARα and PPARγ, which are involved
in pro-apoprotein A1 [112].
Individuals with IR (many HD patients have IR or DM) are known to have an increased
rate of apo A-1 catabolism and an increase in hepatic lipase activity [83]. The study by Chee
Heng et al, 2012 also found that apo A1 expression is higher among individuals who received
TRF among both young and old individuals. This study was not done on ESRD patients [47].
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Individuals with IR and CKD tend to have decreased HDL level due to an increase in the
fractional catabolic rate of apo A-1. Apo A-1 catabolic rate is increased in dialysis patients [108].
The higher level of HDL-C and apo A1 in TRF (week twelve) can not only be justified by
the failure of its clearance due to ESRD and HD. We would see the same increase in the P group
if that was the case. Alteration of CETP activity may thus explain alteration of TG-cholesterol
shuttle between apo A1 and apo B containing lipoproteins (HDL and VLDL/LDL, respectively).
We saw an increase of CETP activity at week twelve followed by reduction of CETP activity
among TRF group in week sixteen (Figure 3.5). This goes with the elevation of HDL-C in week
twelve among the TRF group. Our data showed an increase in normalized HDL-C and a reduction
in normalized TG among the TRF group in both weeks. We conducted a correlation test between
CETP activity and TG as well as between HDL-C and apo A1 during weeks twelve and sixteen to
confirm. There was a positive correlation between CETP activity and TG concentration (Figures
3.6 and 3.7) and between HDL and Apo A1 (Figure 3.8 and 3.9). Correlation studies answered
our speculation and confirmed our findings.
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Table 3.1: Lipid profiles
Baseline

Week 8

Week 12

Week 16

Placebo

TRF

P

Placebo

TRF

P

Placebo

TRF

P

Placebo

TRF

P

(n=40)

(n=41)

Value

(n=36)

(n=39)

Value

(n=34)

(n=38)

Value

(n=29)

(n=38)

Value

TC
(mg/dl)

178±42

183±49

NS

153±32

157±36

NS

140±31

141±43

NS

148±37

145±44

NS

TG
(mg/dl)

109±63

153±21

NS

105±52

139±86

0.04

100±57

113±47

NS

95±48

103±44

NS

44±12

42±13

NS

51±14

51±15

NS

53±13

63±15

0.009

54±11.8

58±18

NS

LDL-C
(mg/dl)

112±38

110±48

NS

80±31

76±35

NS

70±31

56±38

NS

75±33

66±42

NS

TC/HDL-C
ratio

4.20±1.30

4.61±1.72

NS

3.13±1.08

3.20±1.05

NS

2.80±1.01

2.31±0.80

0.046

2.81±1.01

2.60±1.02

NS

HDL-C
(mg/dl)

Abbreviations: TC=Total cholesterol, TG=Triglycerides, HDL-C=High density lipoprotein
cholesterol, LDL-C= Low density lipoprotein cholesterol.
Note: Data are expressed as mean±standard deviation. P values are derived from independent ttest.
Plasma lipids (total cholesterol (TC), total triglycerides (TG), HDL-C, LDL-C, and TC/HDL-C)
for week zero, eight, twelve and sixteen. All values are presented as mean ± SD. P values were
derived using an independent t-test, which tested mean differences between lipid profiles in the
TRF and placebo groups.
P values were derived using an independent t-test, which tested mean differences between lipid
parameters in the TRF and placebo groups with a significance when P < 0.05. NS indicates nonsignificance.
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Figure 3.1: Normalized plasma triglycerides week 8, 12 and 16 mg/dl. Patients were grouped into
P and TRF. Values were presented as mean ± SD.
P values were derived using repeated measures ANOVA with post hoc Bonferroni test, which
tested mean differences in lipid parameters within the groups over the time course. Mean
difference between TRF and placebo groups at particular time points were tested using
independent t-test. P value < 0.05 is considered significance.
The asterices indicate significance (p< 0.05).
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Figure 3.2: Normalized plasma high density lipoprotein-cholesterol mg/dl week 8, 12 and 16
mg/dl. Patients were grouped into P and TRF. Values were presented as mean ± SD.
P values were derived using repeated measures ANOVA with post hoc Bonferroni test, which
tested mean differences in lipid parameters within the groups over the time course. Mean
difference between TRF and placebo groups at particular time points were tested using
independent t-test. P value < 0.05 is considered significance.
The asterices indicate significance (p< 0.05).
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Figure 3.3: Normalized plasma TC/HDL-C ratios week 8, 12 and 16 mg/dl. Patients were
grouped into P and TRF. Values were presented as mean ± SD.
P values were derived using repeated measures ANOVA with post hoc Bonferroni test, which
tested mean differences in lipid parameters within the groups over the time course. Mean
difference between TRF and placebo groups at particular time points were tested using
independent t-test. P value < 0.05 is considered significance.
The asterices indicate significance (p< 0.05).
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FFIGURE 3.4: Plasma apoprotein A1 measures mg/dl in P and TRF groups. Values were
presented as mean ± SME. Number of initial participants was 35 P and 39 TRF at week 12 and 34
P and 38 TRF and week 16.
P values were derived using an independent t-test, which tested mean differences between lipid
parameters in the TRF and placebo groups with a significance when P < 0.05.
The asterix indicates significance (p< 0.05).
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FIGURE 3.5: Cholesteryl ester transfer protein activity test (pmol/ ul plasma/hr) in placebo and
TRF groups. Values were presented as mean ± SME. Number of initial participants was 35 P and
39 TRF at week 12 and 34 P and 38 TRF and week 16.
P values were derived using an independent t-test, which tested mean differences between lipid
parameters in the TRF and placebo groups with a significance when P < 0.05.
The asterices indicate significance (p< 0.05).
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Figure 3.6: Correlation between plasma TG (mg/dl) and CETP activity (pmol/ ul plasma/hr) for
week 12. Pearson correlation was done for statistical analysis with r=0.260, p= 0.025.
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Figure 3.7: Correlation between plasma TG (mg/dl) and CETP activity (pmol/ ul plasma/hr) for
week 16. Pearson correlation was done for statistical analysis with r=0.475, p= 0.000.
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Correlation between HDL-C and Apo A1 (week 12)

Figure 3.8: Correlation between HDL (mg/dl) and apoA1 (mg/dl) for week 12. Pearson
correlation was done for statistical analysis with r=0.378, p= 0.001.
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Correlation between HDL-C and Apo A1 (week 16)

Figure 3.9: Correlation between HDL (mg/dl) and apoA1 (mg/dl) for week 16. Pearson
correlation was done for statistical analysis with r=0.295, p= 0.014.
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CHAPTER 4: SUMMARY AND CONCLUSION
CKD and ESRD are characterized by changes in blood level of lipoprotein, their sizes, and their
function. The alterations in the enzymes that carry on the inter-change between cholesterol and
triglycerides including CETP play major roles along with deficiencies in receptors removal [12,
32, 39, 98, 108]. Numerous studies found that CKD and uremia do not only cause low HDL,
elevated TG and alteration of CETP activity in HD patients, but also alter HDL composition and
function [113, 114].
The elevated level of TG among HD patients (both P and TRF groups) might be explained
by dysfunctional clearance of VLDL and lower function of HL [38, 98,108]. Studies also revealed
that HDL in CKD and HD patients has different proteonomic composition [114]. IR and other co
morbidities also would lead to such metabolic picture of these patients. Many of our patients have
diabetes. Advanced DM and metabolic syndrome are major risk factors for CKD and IR is also
associated with dyslipidemia and CKD complications [16, 21]. We found an increase in plasma
HDL-C and reduction in plasma TG among the TRF patients during week twelve and sixteen.
Normalization revealed a statistically significant increase of HDL-C and reduction of TG in the
TRF group (week 12 and 16). We also found a reduction in TC/HDL-C among TRF patients
because HDL increased. Our data would imply a lipid lowering or modifying effect of TRF,
which requires future studies.
An attempt was made to explain the changes in HDL-C and TG metabolism by measuring
apo-A1, which is the major apoprotein found in HDL and by measuring CETP activity, which is a
major enzyme involved in cholesterol-TG shuttle between apo-B and apo A1 lipoproteins.
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We found positive correlation between HDL-C and ApoA1 (weeks 12, 16; respectively),
which ought to be further explained based on the understanding of HDL metabolism. The
enzyme CETP transfers TG from apo-B lipoprotein to apo-A (HDL subtypes). CETP also leads to
remodeling of the size and the structure of HDL [39, 98, 114]. The transformation of spherical
HDL to a smaller size HDL is carried on by CETP [105, 111, 113]. HDL subunits (apo A1 and
apo A1/A2) are also altered in patients with CKD which explains their altered cardio protective
activity [114]. Apo-A1 catabolism and clearance is also reduced because of the alteration of its
renal clearance in HD patients [83, 108]. The increase of free apo- A1 among TRF group in week
twelve mirrored the increase in HDL-C [109]. If the increase in apo A1 among TRF at week
twelve was only caused by lack of renal clearance because of HD and the fact the kidneys
catabolize apo-A1, we would have seen elevation in apo A1 in both groups and throughout the
study. This was not the case.
We measured CETP activity, and there was higher activity of CETP in the P group (week
twelve), while CETP activity in the TRF group showed reduction at week sixteen. We conducted
a correlation study between CETP and TG (suggesting TG activity transfer) and between HDL-C
and apo A1 in week twelve and sixteen to verify if there was consistency. Correlation studies
were positive in both weeks confirming our findings. The data suggested a potential effect of TRF
on CETP activity in the TRF group that would explain the elevation of HDL-C, apo A1 and the
reduction of TG.
We concluded that TRF might have reduced CETP activity, lowered TG and raised HDLC and apo A1. We concluded that TRF is potentially beneficial for HD patients because our data
showed improvement in lipid profile in TRF group (lowering TG and increasing HDL-C).
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Further studies
Further studies may be required in order to verify and illicit the mechanism(s) which TRF affect
lipid profile in HD patients. This requires a larger number of patients and a potential increase in
the study duration or the dose of T3 based on their tolerance, co-morbidities and drug treatments.
A multi-center research study is thus required to conduct research and assess the time-course and
the potential improvement with giving a higher or modified dose of TRF on human patients with
ESRD with HD and PD. The goal is to elicit the effect of TRF, the effect of each of the four
individual TRF isomers or the comparison between TRF isomers and those of tocopherols and/or
with other neutraceuticals including antioxidants and fish oil may be warranted. The following
studies are suggested:

A) To conduct genomic-proteonomic studies eliciting the effect of TRF on lipid
transcriptional regulation, synthesis, and receptors in patients with ESRD with and without HD or
PD. B) To conduct a study eliciting the effect of TRF on metabolism of various apo-As and apo B
lipoproteins and various regulatory lipoprotein enzymes such as CETP in patients with ESRD. C)
To further elicit the effect of T3 on the associated co-morbidities and their interaction with the
other medical (lipid lowering drugs, ant diabetics, antihypertensive, etc.) and nutritional
interactions on patients with ESRD with HD or PD in order to elicit better understanding and
clinical approach.
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Chronic hemodialysis (HD) patients have an increased risk of cardio vascular diseases (CVD)
driven by dyslipidemia, oxidative stress and inflammation. Vitamin E isomers (tochopherols and
tocotrienols) are fat-soluble anti oxidants. Tocotrienol isomers (T3) are fewer studies than
tochopherol isomers, but they have multifaceted effects on oxidative stress, inflammation and
lipid metabolism.
We investigated the lipid modifying effects of tocotrienol rich fractions (TRF) on CKD
patients receiving HD in a randomized, placebo-controlled, double-blind parallel trial on 81
patients (43M, 38F). Subjects (n=41) were given 220 mg/day of either TRF (180mg TRF,
comprising of 34% αT3, 3%βT3, 50% γT3, 13%δT3 and 40 mg α- tocopherol), or placebo (n=40)
which provided 0.24 mg T3 and 0.44 mg α-tocopherol.
We used standard kits to measure lipid profile=[plasma triglycerides (TG), plasma total
cholesterol (TC), HDL-cholesterol (HDL-C), LDL- cholesterol (LDL-C) using Friedwald
equation, and the corresponding TC/HDL-C ratios] during stating point, week 8, week 12 and
week 16. Statistical analysis used double t-test and for mean differences between TRF and
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placebo groups with p<0.05 as significant. We found that TG was progressively declined in the
TRF group while HDL-C improved at week 12 and 16(p<0.05). We evaluated CETP activity and
apo A1 using a fluoremetric essay and Elisa, respectively to further evaluate HDL and apo B
lipoprotein metabolism.
We found an increase in plasma apo A1 among TRF group at week 12 as compared with
placebo, while week 16 changes were attributed to depressed CETP activity. We concluded that
TRF supplements improved lipids in this HD group. A multi-center trial is needed to further study
the mechanism which TRF work, and with higher doses of TRF.
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